SCHEMBL14788710

SCHEMBL14788710

CC#Cc1ccc2cc(Br)ccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP1B1 Q16678 2/20 0.52
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
CYP2A6 P11509 2/20 0.46
NCEH1 Q6PIU2 1/20 0.36
BACE1 P56817 2/20 0.34
LMNA P02545 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ASIC3 Q9UHC3 2/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
ERN1 O75460 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260199 0.78 CYP1A2 (0.71) CYP1A1CYP1A2CYP1B1ALDH1A1CYP2A6
SCHEMBL1666787 0.77 CYP1A1 (0.52) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL19497056 0.77 CYP1A2 (0.56) CYP1A1CYP1A2CYP1B1KDM4EALDH1A1
SCHEMBL29946581 0.75 CYP1A2 (0.52) CYP1A1CYP1A2CYP1B1TDP1
SCHEMBL22750625 0.75 CYP1A2 (0.52) CYP1A1CYP1A2CYP1B1TDP1
SCHEMBL14790477 0.74 CYP2A6 (0.38) CYP1A1CYP1A2CYP1B1MAPTKDM4E
SCHEMBL2344274 0.74 CYP2A6 (0.50) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL744467 0.74 CYP2A6 (0.50) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL4769651 0.74 GRM5 (0.47) CYP1A1CYP1A2CYP1B1ALDH1A1GRM5
SCHEMBL192166 0.74 CYP2A6 (0.77) CYP1A2MAPTKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 CYP1A1 4540/4885CYP1A2 4548/4885CYP1B1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.